Studies demonstrate that approximately 65-82 percent of patients with Crohn’s disease (CD) report at least some degree of bowel urgency, but this symptom is largely underrecognized by gastroenterologists and health care professionals (HCPs) caring for patients with inflammatory bowel disease (IBD). There is a lack of awareness and appreciation of the impact of bowel urgency in patients with CD as it is most commonly associated with ulcerative colitis. Bowel urgency in patients with CD results in emotional and social stress, leading to stigma, feelings of isolation, and impacting all aspects of daily life for patients. Bowel urgency is not widely incorporated into clinical assessment indices or clinical trial endpoints for CD, despite being a pivotal symptom influencing patient health-related QoL (HRQoL) and a potential indicator of uncontrolled intestinal inflammation.
In this CMEO Outfitters recorded symposium, expert faculty discuss recognizing the frequency of bowel urgency in patients with CD and the impact on patient QoL, incorporating assessments for bowel urgency through symptom evaluation, and engaging patients in open communication about their bowel urgency as part of shared decision-making in order to improve clinical outcomes, and the faculty also review real-world patient cases.
Learning Objectives:
At the conclusion of this activity, learners will be able to better:
- Recognize the frequency of bowel urgency in patients with CD and the impact on patient quality of life.
- Incorporate assessments for bowel urgency as part of thorough symptom evaluation for patients with CD.
- Engage patients in open communication about their bowel urgency as part of shared decision-making in order to improve clinical outcomes.
Faculty:
Marla Dubinsky, MD
Professor of Pediatrics and Medicine
Co-Director, Susan and Leonard Feinstein IBD Clinical Center
Director, Marie and Barry Lipman IBD Preconception and Pregnancy Clinic
Icahn School of Medicine Mount Sinai New York
Chief, Division of Pediatric GI and Nutrition
Mount Sinai Kravis Children’s Hospital
New York, NY
Tauseef Ali, MD, AGAF
Medical Director
SSM Health Crohn's and Colitis Center
Medical Executive Director
SSM Health Digestive Care
Clinical Associate Professor
University of Oklahoma Health Sciences Center
Oklahoma City, OK
Millie D. Long, MD, MPH, AGAF
Professor of Medicine
Vice-Chief for Education
Director, Gastroenterology and Hepatology Fellowship Program
Division of Gastroenterology and Hepatology
University of North Carolina
Chapel Hill, NC
Disclosures
Dr. Dubinsky reports the following financial relationships:
Advisory Board and Consultant: AbbVie Inc.; Abivax; AstraZeneca; Bristol Myers Squibb Company; Janssen Biotech, Inc.; Lilly; Merck & Co., Inc; Pfizer Inc.; Prometheus Biosciences; Prometheus Laboratories; and Takeda Pharmaceuticals U.S.A., Inc.
Dr. Ali reports the following financial relationships:
Advisory Board: AbbVie Inc. and Janssen Pharmaceuticals, Inc.
Consultant: AbbVie Inc.; Boehringer Ingelheim; E.R. Squibb & Sons, L.L.C.; and Fresenius Kabi USA
Research Support: AbbVie Inc.; Arena Pharmaceuticals; AstraZeneca; and Celgene Corporation
Speakers Bureau: AbbVie Inc.; E.R. Squibb & Sons, L.L.C.; Janssen Pharmaceuticals, Inc.; and Takeda Pharmaceuticals U.S.A., Inc.
Dr. Long reports the following financial relationships:
Consultant: AbbVie Inc.; Bristol Myers Squibb Company; Intercept Pharmaceuticals, Inc.; Janssen Pharmaceuticals, Inc.; Lilly; Pfizer Inc.; Prometheus Biosciences, Inc.; Takeda Pharmaceuticals U.S.A., Inc.; and Target RWE
Research Support: Lilly; Pfizer Inc.; and Takeda Pharmaceuticals U.S.A., Inc.
The following individuals have no financial relationships to disclose:
Rebecca Vargas-Jackson, MD (Peer Reviewer)
Shirley Michelle Franks, MSN, APRN, FNP-BC (Peer Reviewer)
Susan Perry (Planning Committee)
Kasey Brandt, PharmD (Planning Committee)
Susan H. Yarbrough, CHCP (Planning Committee)
Sandra Caballero, PharmD (Planning Committee)
Sharon Tordoff (Planning Committee)
Accreditation Statement
The AGA Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The AGA Institute designates this enduring material for a maximum of .75 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
In accordance with the ACCME's Standards for Integrity and Independence in Accredited Continuing Education, all faculty and planning partners must disclose all their financial relationships with ineligible companies held within the past 24 months. The AGA Institute implements a mechanism to identify and mitigate all conflicts of interest prior to delivering the educational activity to learners.
CME expiration date: Sept. 29, 2024
Sponsor:
This activity is supported by an educational grant from Lilly.